Eagle Pharmaceuticals (EGRX) Reiterates 2023 Adjusted EBITDA and EPS Guidance
Eagle Pharmaceuticals, Inc. (Nasdaq: NASDAQ:) (“Eagle” or the “Company”) today reiterated its previously issued guidance for the 2023 fiscal year. Full-year 2023 Adjusted non-GAAP EBITDA is expected to range from $78.0 to $84.0 million and Adjusted non-GAAP earnings per share is expected to range from $4.40 to $4.70.
“Based on the strength of our business and product pipeline, we are reiterating our recently increased guidance and believe Eagle is on the path to generating sustained long-term growth,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.
#Eagle #Pharmaceuticals #Reiterates #Adjusted #EBITDA #EPS #Guidance #Investing.com
